Andrew Cheng Sells 6,620 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng sold 6,620 shares of the company’s stock in a transaction on Wednesday, June 18th. The stock was sold at an average price of $54.84, for a total transaction of $363,040.80. Following the completion of the transaction, the chief executive officer now directly owns 549,867 shares in the company, valued at approximately $30,154,706.28. The trade was a 1.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Andrew Cheng also recently made the following trade(s):

• On Tuesday, June 10th, Andrew Cheng sold 37,837 shares of Akero Therapeutics stock. The stock was sold at an average price of $54.05, for a total transaction of $2,045,089.85.
• On Monday, May 12th, Andrew Cheng sold 30,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $41.48, for a total transaction of $1,244,400.00.
• On Thursday, April 10th, Andrew Cheng sold 30,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $35.23, for a total transaction of $1,056,900.00.

Akero Therapeutics Stock Down 1.3%

Shares of NASDAQ:AKRO opened at $54.20 on Friday. Akero Therapeutics, Inc. has a 52-week low of $21.02 and a 52-week high of $58.40. The firm has a fifty day moving average of $45.88 and a 200 day moving average of $41.17. The firm has a market capitalization of $4.32 billion, a PE ratio of -27.79 and a beta of -0.16. The company has a debt-to-equity ratio of 0.03, a quick ratio of 16.80 and a current ratio of 16.80.

Akero Therapeutics (NASDAQ:AKRO) last posted its quarterly earnings results on Monday, May 12th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.01) by $1.91. As a group, research analysts anticipate that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Institutional Trading of Akero Therapeutics

Several institutional investors have recently added to or reduced their stakes in AKRO. Northwest & Ethical Investments L.P. purchased a new stake in Akero Therapeutics during the first quarter valued at about $32,000. GF Fund Management CO. LTD. purchased a new stake in Akero Therapeutics during the fourth quarter valued at about $41,000. Sterling Capital Management LLC boosted its position in Akero Therapeutics by 764.3% during the fourth quarter. Sterling Capital Management LLC now owns 1,789 shares of the company’s stock valued at $50,000 after buying an additional 1,582 shares during the period. PNC Financial Services Group Inc. boosted its position in Akero Therapeutics by 30.8% during the first quarter. PNC Financial Services Group Inc. now owns 1,658 shares of the company’s stock valued at $67,000 after buying an additional 390 shares during the period. Finally, Quarry LP purchased a new stake in Akero Therapeutics during the fourth quarter valued at about $83,000.

Wall Street Analyst Weigh In

AKRO has been the topic of several research analyst reports. Morgan Stanley reaffirmed an “overweight” rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. HC Wainwright upped their target price on shares of Akero Therapeutics from $72.00 to $75.00 and gave the stock a “buy” rating in a research report on Monday, March 3rd. Citigroup cut their target price on shares of Akero Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a research report on Tuesday, May 13th. Finally, Bank of America upped their target price on shares of Akero Therapeutics from $63.00 to $64.00 and gave the stock a “buy” rating in a research report on Tuesday, May 27th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Akero Therapeutics presently has a consensus rating of “Buy” and an average price target of $82.50.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.